Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials

Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy

(2018) Haruhiko Ozaki et al.   DIGESTION

Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection

(2018) Wen Zhong Liu et al.   HELICOBACTER

Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis

(2017) James K.Y. Hooi et al.   GASTROENTEROLOGY

Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale

(2017) Bor-Shyang Sheu et al.   HELICOBACTER

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort

(2015) Corinne Gower-Rousseau et al.   GUT

Primary antibiotic resistance ofHelicobacter pyloristrains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study

(2015) Yue-Xi Zhang   WORLD JOURNAL OF GASTROENTEROLOGY

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Fourth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection

(2013) et al.   Journal of Digestive Diseases

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

M1096 High Dose vs. Standard Dose Proton Pump Inhibitor Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis

(2008) Albert Villoria et al.   GASTROENTEROLOGY

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology